How long is Prolia (denosumab) treatment usually continued?
Prolia is given as an injection every 6 months. Patients are typically kept on ongoing treatment rather than a fixed, short “course,” because Prolia works by continuously lowering bone resorption. Stopping it can lead to a rebound increase in bone turnover and bone loss risk.
What happens if you stop Prolia?
Stopping Prolia can trigger rapid bone loss and raises the risk of multiple vertebral fractures, particularly in people who are not transitioned to another osteoporosis medicine afterward. This is why clinicians usually plan an “exit strategy” before stopping Prolia.
If Prolia is stopped, how is treatment transitioned?
When Prolia is discontinued, patients are commonly switched to a bisphosphonate to help prevent rebound bone loss and fractures. The exact medication and timing depend on the person’s fracture risk, kidney function, and prior osteoporosis history, and the plan is set by the treating clinician.
Can you take Prolia for many years?
Prolia is used long term in appropriate patients. Many people stay on treatment for multiple years under monitoring. The decision to continue is usually based on ongoing fracture risk and how well the treatment is working, rather than an automatic end date.
When do doctors reassess whether to continue Prolia?
Clinicians typically reassess periodically using factors like prior fractures, bone mineral density (DEXA) results, age, and other risk factors. The goal is to continue therapy while the patient remains at enough fracture risk to justify ongoing injections, and to ensure a safe transition if stopping becomes necessary.
Are there special duration considerations for kidney disease?
Prolia can be used in patients with reduced kidney function, but the medical team still monitors closely because low calcium levels (hypocalcemia) can be a concern. That monitoring can affect how clinicians plan continuity and timing.
What patients ask about “how many shots” before stopping
Patients often want a target number of doses. There usually is no universal “final” number; the safe approach is typically individualized. If a patient needs to stop for any reason (side effects, travel/logistics, moving care), the clinician typically schedules a transition to another osteoporosis therapy rather than stopping without follow-up.
Sources: no citations available from the provided information set.